An 18-year survivor of neuroblastoma is believed to represent the longest reported remission to date in a patient treated with chimeric antigen receptor (CAR) T cell therapy.
Read More
A metabolic vulnerability in neuroblastoma could be exploited to overturn these tumors’ resistance to therapy.
Read More
Restoring function of the molecular clock blocks tumor growth in advanced neuroblastoma and can make tumors more sensitive to conventional chemotherapy.
Read More
An ongoing clinical trial shows that human CAR NKT cells are safe and, in 1 of 3 patients, induced regression of metastatic lesions.
Read More
Understanding the cancer risk in children with birth defects has been a challenge. Although scientific studies suggest that birth defects increase the risk of cancer,
Read More
Neuroblastoma is the most common extracranial solid cancer in children, and patients with high-risk disease are challenging to treat. In April, during the annual meeting of
Read More